Gene · 1316
KLF6: KLF transcription factor 6
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KLF6: KLF transcription factor 6. Genes, record 1316. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1316
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q99612 | Krueppel-like factor 6 | 283 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents37
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4805378 A1 | 2026-09-16 | 705 | Q99612 | Espacenet |
| EP 4705462 A2 | 2026-03-11 | 131 | Q99612 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 50975 | Q99612 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 14383 | Q99612 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15220 | Q99612 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 14383 | Q99612 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 15220 | Q99612 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 15220 | Q99612 | Espacenet |
| JP 2024534404 A | 2024-09-20 | 92 | Q99612 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 15059 | Q99612 | Espacenet |
1 to 10 of 37
See all 37 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,888
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KLF6 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 13 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| P30DK020541 | NYR-Diabetes Research Center (NYR-DRC) | 5 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 4 | 2025 |
| P30CA034196 | Cancer Center Support (CORE) Grant | 4 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 4 | 2025 |
| P30EY014800 | University of Utah Core Vision Research Grant | 4 | 2025 |
| P30EY014801 | Miami Center for Vision Research | 4 | 2025 |
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 4 | 2025 |
| R01DK052230 | Regulation of Intestinal Epithelial Cell Proliferation | 4 | 2025 |
1 to 10 of 1,888Source NIH's project files
See all 1,888 nih grantsPapers2,770
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cysteine supplementation reverses immune dysfunction in cancer patients with severe COVID-19. | medRxiv | 2026 | 42818159 | PubTator, text mining | PubMed |
| Integrated chromatin accessibility and transcriptomic profiling provide insights into inflammation-associated endothelial remodeling in capillary malformations. | Cell Signal Inflamm Dis | 2026 | 42788004 | PubTator, text mining | PubMed |
| Biochanin A promotes KLF6 stabilization to induce ferroptosis and suppress colorectal cancer progression. | Cell Signal | 2026 | 42754129 | PubTator, text mining | PubMed |
| KLF transcription factors in metabolic kidney disease: from podocyte protection to tubulointerstitial fibrosis. | Int Urol Nephrol | 2026 | 42753072 | PubTator, text mining | PubMed |
| Analysis of Allele-Specific Expression Highlights Novel Participants of Empagliflozin-Driven Effects on T2DM-Associated Regulatory Pathways. | Int J Mol Sci | 2026 | 42653207 | PubTator, text mining | PubMed |
| Design, synthesis, and preliminary antiproliferative evaluation of azetidine-functionalized pyrrolo[2,3-d]pyrimidines with integrated computational studies. | J Biomol Struct Dyn | 2026 | 42627359 | PubTator, text mining | PubMed |
| Regulatory roles and translational potential of the Kruppel-like factor family in liver disease. | ILIVER | 2026 | 42598083 | PubTator, text mining | PubMed |
| KLF6-driven macrophage-to-myofibroblast transition promotes PD-L1-mediated immune evasion in bladder cancer. | Int Immunopharmacol | 2026 | 42574804 | PubTator, text mining | PubMed |
| Inhalable Mucoadhesive Redox-Triggered Nanotherapeutics for p53-Mediated Lung Cancer Therapy and Metastasis Suppression. | Adv Healthc Mater | 2026 | 42498986 | PubTator, text mining | PubMed |
| Mesothelial cell senescence induced by high glucose in peritoneal dialysis drives fibroblast activation and peritoneal fibrosis through KLF6-mediated activation of TGF-β pathway. | Mol Cell Biochem | 2026 | 42418120 | PubTator, text mining | PubMed |
1 to 10 of 2,770
See all 2,770 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1316
GET https://conductscience.org/api/genes/v1/1316/patents?page=2